School of Psychiatry, University of New South Wales, and Black Dog Institute, Sydney, Randwick, Australia.
J Affect Disord. 2013 Jul;149(1-3):46-55. doi: 10.1016/j.jad.2012.10.002. Epub 2012 Nov 8.
While there have been many studies comparing direct and indirect costs engendered individually and nationally by those with unipolar (UP) and bipolar (BP) disorders, there has been no previous study comparing costs across the bipolar I (BP I) and bipolar II (BP II) disorders.
We examine direct and indirect costs attributable to a mood disorder in a sample of 44 BP I, 102 BP II and 279 UP patients attending a tertiary referral clinic, and with comparable illness durations of some 20 years and comparable treatment durations. We calculated direct and indirect costs incurred for their lifetime of illness based on relevant cost structures, in Australian dollars.
The mean lifetime indirect costs for BP I patients was $134,318, as against $76,821 for BP II and $68,347 for UP patients, joining with respective health care costs of $26,353, $17,580 and $27, 237, to generate total costs of $160,671/BP I patient, $94,401/BP II patient and $95,584/UP patient. BP I patients differentiated most distinctly in costs as a consequence of a higher prevalence of government benefits, time off work and longer periods in hospital. UP patients had more stable work histories than both BP sub-sets. BP II patients were less likely to be hospitalised than both the BP I and UP patients.
Being drawn from a tertiary referral clinic, the study sample is not necessarily representative, with this nuance potentially having influenced cost differences between groups.
This is the first cost of illness study directly comparing BP I and BP II patients (and with an additional comparison group of UP patients). Findings indicate that BP I illness generates more direct and indirect costs than BP II illness, while the latter was generally comparable with UP depression in terms of the lifetime cost.
虽然有许多研究比较了单相(UP)和双相(BP)障碍患者个人和国家产生的直接和间接成本,但以前没有研究比较过双相 I 型(BP I)和双相 II 型(BP II)障碍的成本。
我们在一家三级转诊诊所中检查了 44 名 BP I、102 名 BP II 和 279 名 UP 患者的情绪障碍直接和间接成本,他们的疾病持续时间约为 20 年,治疗持续时间也相似。我们根据相关成本结构,以澳元计算了他们一生中因疾病而产生的直接和间接成本。
BP I 患者的平均终身间接成本为 134318 澳元,而 BP II 和 UP 患者分别为 76821 澳元和 68347 澳元,加上各自的医疗保健成本 26353 澳元、17580 澳元和 27237 澳元,BP I 患者的总费用为 160671 澳元/人,BP II 患者为 94401 澳元/人,UP 患者为 95584 澳元/人。BP I 患者的差异最为明显,这是由于政府福利、旷工和住院时间较长的患病率较高所致。UP 患者的工作历史比 BP 两个亚组都更稳定。BP II 患者住院的可能性低于 BP I 和 UP 患者。
该研究样本来自三级转诊诊所,因此不一定具有代表性,这种细微差别可能影响了组间的成本差异。
这是第一项直接比较 BP I 和 BP II 患者(并与 UP 患者的附加比较组)的疾病成本研究。研究结果表明,BP I 疾病产生的直接和间接成本高于 BP II 疾病,而后者在终身成本方面与 UP 抑郁症大致相当。